«

»

Nov 04

Apixaban in atrial fibrillation

In AF most on patients warfarin are unable to continue due to difficulty with regular monitoring. Dabigatran is an approved alternative anticoagulant for these patients.

In addition, apixaban, a factor Xa inhibitor is being tested.

In the AVERROES trial, 5599 AF patients were randomly assigned to either apixaban or aspirin. The study was stopped prematurely because of a clear benefit in favor of apixaban (lower rate of stroke or systemic embolism).

[N Engl J Med 2011; 364:806.]

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>